Source: BioSpace

Bayer : Bayer Jumps on Chinese Partnership Train with Oncology Deal

The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.

Read full article »
Annual Revenue
$50-100B
Employees
50-100K
William N. Anderson's photo - CEO of Bayer

CEO

William N. Anderson

CEO Approval Rating

63/100

Read more